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Antimicrobial stewardship initiatives in secondary care depend on clinicians undertaking 




To assess the feasibility and acceptability of implementing ARK (Antibiotic Review Kit), a 
behaviour change intervention made up of four components (brief online tool, prescribing 
decision aid, regular data collection and feedback process, and patient leaflet) to support 
stopping antibiotic treatment when it is safe to do so among hospitalised patients; before 
definitive evaluation through a stepped-wedge cluster randomised controlled trial. 
 
Methods 
Acceptability of the different intervention elements was assessed over 12-weeks by uptake 
of the online tool, adoption of the decision aid into prescribing practice, and rates of decisions 
to stop antibiotics at review (assessed through repeated point-prevalence surveys). Patient 
perceptions of the information leaflet were assessed through a brief questionnaire. 
 
Findings 
All elements of the intervention were successfully introduced into practice. A total of 132 staff 
encompassing a broad range of prescribers and non-prescribers completed the online tool 
(19.4 per 100 acute beds), including 97% (32/33) of the pre-specified essential clinical staff. 




implementation period, 82% overall (76-90% at each survey) used the decision aid. The 
median antibiotic stop rate post implementation was 36% (range 29-40% at each survey) 
compared with 9% pre implementation (p<0.001). 
 
Conclusion 
ARK provides a feasible and acceptable mechanism to support stopping antibiotics safely at 
post-prescription reviews in an acute hospital setting. 
 







Hospital prescribing accounts for a minority of human antibiotic consumption but is where 
the great majority of broad-spectrum antibiotics are prescribed. 1 Reducing antibiotic overuse 
in hospitals is challenging because patients who present acutely unwell or are critically ill 
require prompt and adequate initial antibiotic therapy. 2, 3 Controlling antibiotic overuse relies 
on regular review and revision of antibiotic prescribing decisions; in the UK National Health 
Service (NHS) ‘Start Smart then Focus’ guides that the continued need for antibiotics is 
assessed at 24-72 hours when more diagnostic information is available and treatment 
response can be assessed.4 Similarly, recommendations from the USA Centers for Disease 
Control and Prevention (CDC) include antibiotic “time-outs” to prompt reassessment of the 
continued need for and choice of antibiotic treatment. 5 
 
Wide-ranging educational and practice resources exist to support hospital antibiotic 
stewardship 6 but significant improvements in hospital antibiotic overprescribing have not 
been achieved. 1, 7 Knowledge, system and behavioral factors combine to make it very hard 
for doctors to take active decisions to stop antibiotics 8 and under 10% of antibiotic 
prescriptions are discontinued at review in the NHS. 9 For these reasons, the Antibiotic Review 
Kit (ARK) intervention was designed and carefully optimised using an integrated person-based 
approach to address the barriers to behaviour change (Santillo et al., Journal of Antimicrobial 
Chemotherapy in press). ARK aims to support prescribing and non-prescribing healthcare 
professionals apply the “review and revise” approach to antibiotic prescriptions for acute and 
general medical inpatients, and specifically to stop antibiotic treatment more often when it is 





The clinical impact of many research programmes evaluating novel antimicrobial prescribing 
interventions is hampered by design and reporting limitations. 10 In particular all stages of 
evaluation should be reported allowing clinicians to understand how potential barriers and 
facilitators have been considered. Ahead of the definitive evaluation of ARK in a multi-centre 
in a stepped-wedge cluster randomised trial we undertook a single-site feasibility study. Here 
we report the practicalities of implementing the ARK-hospital intervention in a single acute 
hospital. We provide evidence for both the feasibility of adapting the intervention according 
to local needs whilst maintaining fidelity to the core elements and acceptability of the 




Approvals were obtained from the South Central – Oxford C Research Ethics Committee 
(17/SC/0034) and Confidentiality Advisory Group (17/CAG/0015). The trial is registered with 
Current Controlled Trials (ISRCTN:12674243). This study has been reported in line with the 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)-AMS tool. 11 
 
Intervention description 
ARK has four components: an online tool, prescribing decision aid (supplementary figure 1), 
data collection and feedback process, and a patient leaflet that are summarised in table I. ARK 
implementation is led by an ARK Champion and Core Team, involving an AMS team member, 
and clinical staff considered essential to the local implementation of ARK. The 




phases, beginning three months before kick-off, covering three months of implementation 
and then addressing sustainability (supplementary figure 2).  
 
Design 
This single site study focused on three key aspects; a) feasibility of adapting ARK to local 
needs, b) feasibility of key intervention components, and c) acceptability of ARK to the 
implementation team and the wider clinical team. The feasibility site was a selected Trust 
from of a network of healthcare professionals involved in stakeholder consultations during 




Brighton and Sussex University Hospitals NHS Trust (BSUHT) is an acute, medium-sized 
teaching hospital delivering secondary and tertiary services across two main sites. ARK was 
implemented on the larger 680-bed site, where approximately 75% of medical admissions 
come through a 32-bed acute medical unit (AMU). Medical patients are referred from primary 
care or the emergency department (ED). Patients who have an anticipated length of stay of 
>72 hours are transferred to an inpatient ward managed by an appropriate general or 
specialist team e.g. respiratory, elderly care, endocrine or gastroenterology.  
 
Before implementation, the Trust’s total antibiotic prescribing (4,711 defined daily doses per 
1000 admissions) reflected national figures (median in England 4,868 (range 1619 to 10475) 
in Q4 2016/17). The Trust used paper-drug charts including an antibiotic prescription page on 




whole time equivalent Consultant Microbiologist) and two full-time antimicrobial 
pharmacists working through an AMS committee, who met monthly with representation from 
infection control, service commissioners and trainees in infection medicine. The AMS 
committee reported upwards to the Trust’s Drugs and Therapeutics Committee (DTC) and the 
Infection Control Committee. In terms of education and training, the Trust used the 
MicroGuideTM platform as a mobile resource containing antibiotic prescribing guidelines and 
other AMS-related educational content. Prescribing practice was monitored through trust-
wide audits, based on the NHS Safety Thermometer (NHS-ST) tool, whereby ward pharmacists 
collect data on antibiotic prescriptions for up to five patients per ward on a monthly basis. 12 




Quantitative data on use of the online training module was collected automatically through 
LifeGuide. Point-prevalence data on use of the Decision Aid categories and antibiotic 
prescribing were collected from paper drug charts using the ARK data collection workbook, 
prior to implementation and at weeks 1, 2, 3, 4, 6, 8 and 12. Data was collected from all 
patients on the AMU, respiratory, elderly care, endocrine and gastroenterology wards who 
had received antibiotics during their current inpatient stay. Data were gathered for each 
antibiotic indication rather than individual agent. Indications were assumed to reflect 
infection as diagnosed by the prescriber and not defined further. Patient views on the patient 
leaflet were elicited through a brief questionnaire (supplementary materials) scored on a 1 to 
7 Likert scale in a small sample of AMU patients who had been prescribed antibiotics and 






Details of how the Core Team locally adapted and implemented each of the four ARK 
intervention components are reported alongside the relevant outcome measures. The 
champion identified key essential staff members who they felt would  facilitate their clinical 
colleagues’ engagement with ARK. These included consultants and training-grade doctors 
from each relevant medical specialty, senior nurses and pharmacists working in the clinical 
areas where ARK was implemented and infection specialist doctors. The primary outcome 
was the proportion of preidentified key essential staff who completed the online training.  
Other usage data for the online tool included the overall number of staff who completed it 
per 100 acute-beds, to reflect levels of staff engagement. Other outcomes reflected the 
process of implementation, specifically the proportion of initial prescriptions that: used the 
Decision Aid categories, were reviewed within 72 hours and had been stopped at review. 
These were all pre-specified in the protocol as secondary outcomes for the main trial. Other 
actions taken at review, i.e. switch agent (narrow/broaden), move from intravenous to oral 
route, or outpatient parenteral antimicrobial therapy (OPAT), were also considered in 
secondary analyses. Targets for ARK to be considered feasible and progress to the main trial 
were that >70% of staff identified by the champion as essential for ARK to be implemented 
should complete the online tool, and that >50% of prescriptions audited should have used the 
Decision Aid. These thresholds were chosen because with no evidence base for estimating 
the level of engagement necessary to achieve changes in prescribing behaviour, >70% 
engagement of key opinion leaders in the hospital and >50% use of the decision aid were felt 






Binary outcomes were assessed using univariable and multivariable logistic regression (or 
Fisher’s exact test if the outcome was identical for all prescriptions in one group), and other 
actions at review using multinomial regression. Evidence for variation across the 
implementation period (weeks 1-12) was assessed using Wald tests, and combined models 
comparing baseline versus post-implementation were used where there was no evidence of 




Core Team and essential clinical staff 
At the feasibility site the Core team included: The Champion (Consultant in Infectious 
Diseases), the Trust’s AMS lead, two Acute Medicine Consultants, two Antimicrobial 
Pharmacists, two Acute Medicine Charge Nurses and three training-grade doctors. The Core 
team received access to the intervention materials in February 2017 to begin planning 
towards implementation on 18th April 2017. The team met four times over the 10 weeks to 
work through the guidance, assign and deliver key tasks. The Champion identified 33 key 
essential staff to promote the wider clinical teams’ involvement with ARK. These included 21 
consultants (9 acute medicine, 4 microbiology and infection, 2 elderly care, 2 endocrine, 2 
critical care, 1 each in respiratory and gastroenterology), 4 training-grade doctors in acute 
and general medicine including the ‘chief’ medical registrar, 4 pharmacists working in acute 
and infection medicine, and 2 acute medicine and 2 infection control nurses. All clinical staff 
were invited to a Grand Round, covering the background and practicalities, 4 weeks before 




teams, nursing staff, pharmacy staff and junior doctors. The details of how the Core Team 
locally adapted and implemented each of the four ARK intervention components can be found 
in table II. 
 
Online tool. In terms of the primary outcome, the proportion of key essential staff who 
completed the online tool was 97% (32/33), exceeding the target of >70%. Including essential 
clinical staff, a total of 175 healthcare professionals registered to use the online tool and 132 
completed it (19.4 per 100 acute beds). Of those completing the tool, 34% (45/132) were 
Consultants, 26% (34/132) were training-grade doctors, 19% (25/132) were nurses, 11% 
(14/132) were pharmacists or pharmacy technicians, 4% (5/132) were other healthcare 
professionals, and 7% (9/132) did not disclose their profession. Staff who completed the 
online tool logged into the website version a mean of 1.65 times (SD: 1.4; median 1, IQR 1-2, 
maximum 12) and spent a median of 14.3 minutes (IQR 10.1,28.2) on it. Although most users 
logged in only once (61%, 80/132), just under a third logged in twice (30%; 40/175), and 9% 
(12/132) logged in three times or more. 
 
Decision Aid. Throughout the 12-week implementation, >75% of audited antibiotic 
prescriptions had applied the Decision Aid categories (figure 1), exceeding the 50% target, 
with no evidence of variation over time post-implementation (heterogeneity p=0.61). More 
prescriptions using the Decision Aid were categorised as “probable” rather than “possible”, 
but the proportion categorised as ‘possible’ increased over the 12-week implementation 
period (heterogeneity p=0.008) (figure 1). 
 




undertook 32 point prevalence audits of antibiotic prescriptions using the ARK data collection 
tool, covering 107 prescriptions pre-implementation (baseline) and 588 post-
implementation. Pre-implementation wards audited included acute medicine (27%; 29/107), 
respiratory (26%; 28/107), elderly care (32%; 34/107), endocrine (10%; 11/107), and 
haematology (5%; 5/107). Post-implementation prescriptions were audited on wards 
implementing ARK, namely elderly care (42%; 246/588), acute medicine (25%; 146/588), 
respiratory (16%; 92/588), endocrine (12%; 70/588) and gastroenterology (6%; 34/588). The 
Core Team delivered a total of 20 sessions to feedback antibiotic prescribing data across these 
four clinical teams. 
 
Patient leaflet. All patients (N=15) rated the leaflet highly on providing all the information 
they needed (mean score (maximum 7)=6.5, SD=0.52), being helpful (6.4, SD=0.63), 
trustworthy (6.5, SD=0.64), and something they would recommend to others (6.2, SD=0.86), 
with 13/15 (87%) stating that they would be likely or extremely likely to recommend the 
leaflet to friends and family taking antibiotics in hospital. The commonest method of 
distribution was in discharge medication bags, meaning that most patients only received the 
leaflet on discharge 
 
Impact on antibiotic review and decision making 
Review within 72 hours of initial prescription 
Throughout the 12-week implementation, >96% of prescriptions were reviewed within 72 
hours (figure 2), remaining approximately stable over time (Fisher’s exact p=0.80). Overall 
review rates increased from 91% (69/76) at baseline to 99% (450/457) post-implementation 






The median antibiotic stop rate across audits post-implementation was 36% (range 29-40%) 
(figure 2) remaining relatively stable over time (heterogeneity p=0.87). Overall, the 
percentage stopping antibiotics by 72 hours increased from 9% (6/69) at baseline to 35% 
(156/450) post-implementation (OR=5.57 [95% CI 2.36,13.16], p<0.001). Post-
implementation, antibiotic stop rates varied significantly according to the Decision Aid 
category, with 48% (51/106) of prescriptions categorised as “possible” stopped by 72 hours 
versus 29% (75/260) “probable” (OR (possible:probable)=2.29 [95% CI 1.44,3.64], p=0.001), 
compared with 36% (30/84) of prescriptions where the Decision Aid was not used. 
 
Other actions taken at review 
Over the 12-week implementation, the proportion of antibiotic prescriptions where no 
change was made declined (150/450 (33%) vs 37/69 (54%) baseline), as did the proportion 
switched to other agents (69/450 (15%) vs 15/69 (22%) baseline, p=0.71 vs ‘no change’) 
(figure 3). The proportion of antibiotics changed from intravenous to oral remained stable 
(75/450 (17%) vs 11/69 (15%) baseline; p=0.16 vs ‘no change’). There was no evidence that 
other actions depended on the Decision Aid category used (p>0.15). No patient started OPAT 
during the study.  
 
Discussion 
This study assessed the feasibility of implementing the novel, multifaceted ARK intervention 
which has been developed to address overprescribing of antibiotics to hospitalised patients. 




medium-sized acute NHS hospital, facing typical pressures of under-staffing and patient 
burden. 13 The percentage of pre-specified essential staff who completed the online tool 
greatly exceeded the target level for progression to full trial evaluation. The tool was also 
completed by a substantial number of front-line healthcare workers encompassing the main 
professional groups involved in antimicrobial treatment. The proportion of initial 
prescriptions using the Decision Aid also substantially exceeded the target threshold at all 
time points. Implementation of ARK was associated with a substantial and sustained increase 
in antibiotic stop rates over the 12-week study period. The sustained use of the Decision Aid 
and the Trust’s decision to adopt it into the antibiotic prescribing process, both long-term and 
Trust-wide, attest to the acceptability of the intervention. The increase in the proportion of 
prescriptions categorised as “possible” over time may be related to an improved 
understanding of the Decision Aid categories over the course of the intervention; the 
importance of the “possible" category in enabling prescribers to change antibiotic 
prescriptions at review was repeatedly emphasised during feedback sessions. Patient 
questionnaire responses indicated that patients received the leaflet very positively; this was 
also confirmed by qualitative interviews with patients (reported elsewhere; Mowbray et al., 
unpublished results). The AMS structures and processes were typical of acute NHS Trusts and 
remained so after the implementation of ARK, incorporating most core recommended 
elements. 14 
Our study has important limitations. Most notably, as a feasibility study we were not seeking 
to establish whether the ARK intervention is effective in reducing antibiotic consumption 
itself. Antibiotic consumption across acute medical patients at a hospital varies markedly 
month by month and over time, with strong seasonality. Assessment of ARK’s impact on 




nationwide stepped wedge cluster-randomised trial with prolonged follow-up to account for 
secular trends and to assess sustainability. For these reasons, we have not investigated 
patient-level outcomes. Robust assessment of safety in terms of preserving good clinical 
treatment outcomes while reducing antibiotic exposure is a key part of assessing a 
stewardship intervention and this will also be assessed in the full trial. Of note, the ARK 
intervention aims to support clinicians’ “review and revise” antibiotic decision making in line 
with ‘Start Smart then Focus’ recommendations, 4 rather than demonstrate whether this is of 
itself a safe and effective strategy to mitigate risks of antimicrobial overuse. This approach 
closely follows recommendations followed in other healthcare systems, for example the 
CDC’s Core Elements of Hospital AMS Programmes which includes ‘antibiotic time outs’ to 
review prescribing decisions. Time-limiting initial antibiotic prescriptions has not, as far as we 
know, been evaluated in the NHS previously but has been found in the United States to reduce 
the total consumption of antibiotics and the use of inappropriate agents without negatively 
impacting mortality. 15, 16 As a measure of acceptability of the online learning, we could have 
reported the proportion of staff who completed it using either the number of staff who work 
in the areas where ARK was implemented or of staff invited to do the on line learning. 
However, the way the learning was made available to healthcare workers involved in acute 
medicine and general medicine meant neither of these denominators could be obtained. 
Using the proportion of key essential staff gives a reliable but restricted measure. We can not 
discount the possibility that other staff members who could have been key influencers were 
not identified by the ARK Champion. However, this did not appear to have a negative impact 
on other study outcomes. The number of 19.4 staff trained per 100 acute beds is hard to 
interpret but the fact that 132 staff found time to do the online learning in a busy trust 




site, the results cannot be generalised to non-hospital settings and may be less applicable to 
hospitals with different infrastructures, which may be the case in other countries. 
Nonetheless, an important strength of our study is that we have been able to characterise 
the delivery and uptake of a novel multi-faceted intervention in a setting typical of the wider 
NHS environment in which its definitive evaluation will be undertaken. This study shows that 
the ARK intervention is adaptable and can be applied to other acute hospitals within the UK. 
It has informed how these sites can prepare for implementing ARK and has led to multiple 
additions to the implementation guidance e.g. more emphasis on how to incorporate the 
patient leaflet component.  All materials developed in this feasibility study (such as slide sets, 
email and letter templates, poster and drug chart templates) form the basis of a resources 
set that is available to sites implementing ARK during the full trial. Another product has been 
the establishment of a national network involving Champions and their colleagues at sites 
involved in the full trial evaluation, a forum where they can communicate and a repository 
where they can share resources.  
 
Conclusions 
In conclusion, we have established the feasibility and acceptability of a complex behaviour 
change intervention aimed at increasing the rate of antibiotic stop decisions among acute 
medical admissions at a single acute NHS Trust. There is promising evidence that the ARK 
intervention may be able to motivate and support better adherence to existing guidance to 
stop antibiotics at review. A nationwide stepped-wedge randomised controlled trial is 
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Table I. The four components of the ARK intervention  
Component Description 
Online tool A brief (7-10 minute) online tool on the University of Southampton LifeGuide platform 
(https://www.lifeguideonline.org) that promotes motivation and confidence to 
implement “review and revise”, by discussing the risks and benefits associated with 
antibiotic treatment duration decisions and introducing the Decision Aid 
Decision Aid* Allows prescriber to acknowledge and record the degree of certainty around an initial 
antibiotic prescription and link this to the review decision, using two key antibiotic 
prescribing moments. 
 
1. Initial prescription, at which point prescriptions are categorised as based on either: 
• “possible” risk from infection (infection less likely but antibiotics are being 
prescribed until serious infection can be excluded) or 
• “probable” risk of infection (infection is likely but more information is required 
before finalising the diagnosis/treatment) 
 
2. Review, at which point prescriptions can either be stopped (where there is not a clear 
justification for continued treatment) or finalised (where a senior/specialist decides on 




Uses point-prevalence data gathered with a Microsoft Excel workbook (Microsoft 
Corporation, Redmond, USA) to inform brief, frequent and supportive discussions with 
clinical teams about Decision Aid use and rates of stopping antibiotics, reinforcing 
learning about antibiotic prescribing decisions 
Patient leaflet Explains the "review and revise” process, why antibiotics may be stopped, then 
potentially restarted, and gives safety-netting advice 





Table II. Description of the local adaptation and implementation of the ARK intervention components 
Component Local adaptation and implementation 
Online tool • Approved by The Department of Medical Education to be available on the Trust’s e-
learning platform 
 
• Approximately 1 month before implementation, the ARK Champion invited the 33 
members of essential staff to complete the tool 
 
• On implementation, the Medical Director sent a trust-wide email inviting all medical 
staff to complete the tool 
 
• Further email invitations and publicity within the 12-week implementation period 
also contained a link to the online tool 
Decision Aid* • A new antibiotic prescription section of the paper drug chart was designed to 
incorporate the Decision Aid and containing an: 
 
- Initial prescription section with “possible” and “probable” categories, allowing 
a maximum of 3 calendar days of antibiotics 
 
- Finalised prescription section, allowing 6 calendar days to be administered 
  
• In the 2 months prior to implementation it was piloted across a range of medical 
specialties and approval for the final design (supplementary figure 3) was gained 
from the Trust’s DTC before implementation 
  
• During the study it was administered as an A4-size sticker placed over the existing 
antibiotic page of all drug chart in ED and AMU but post-implementation the DTC 




• Forums used included handover meetings, multidisciplinary team meetings, 
governance meetings, teaching sessions and informally on the wards  
 
• To reinforce understanding of the Decision Aid a number of brief case vignettes 
based on current or recent inpatients were also discussed (supplementary figure 4) 
Patient leaflet • Approved by the Trust’s DTC with the addition of local contact details and the 
Trust’s logo 
 
• Printed copies available in the AMU’s doctors’ office, ward bays and clinical room 
 
• Healthcare professionals were encouraged through the online tool, posters, email 
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